BioSpace News Archive

Trinity Life Sciences, a leader in global life science commercialization solutions, announced the winners of the TGaS Best of Benchmark Awards.

TRxADE Telehealth Subsidiary Bonum Health to Provide Affordable Telemedicine Services to Patients at Leading Grocery Store Chain

Teknova , a leading manufacturer of cell culture media and supplements, protein purification buffers, and molecular biology reagents, announced today that Matt Lowell has joined the company as Chief Financial Officer (CFO). Lowell brings with him nearly 20 years of financial and strategic leadership experience

Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce that it has now launched the e-commerce portal selling Allied’s CBD products in the United States

Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today the publication of research findings from a study that was performed by scientists at Neuropathix and the Lewis Katz School of Medicine at Temple University.

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, reported financial results for the first quarter ended March 31, 2021 and reviewed business highlights.

Abbott (NYSE: ABT) today announced a new trial focused on improving the treatment for people simultaneously battling both atrial fibrillation (AFib) and heart failure

Zogenix, a global biopharmaceutical company developing and commercializing rare disease therapies, announced financial results for the three months ended March 31, 2021, and provided a corporate update.

Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the first quarter of 2021.

Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced financial results for the first quarter ended March 31, 2021 and provided a business update.